ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Start-ups

Arizona State spin-off OncoMyx Therapeutics raises $25 million to develop oncolytic viruses

by Ryan Cross
June 15, 2019 | APPEARED IN VOLUME 97, ISSUE 24

 

OncoMyx Therapeutics has raised $25 million in series A financing to develop and test oncolytic viruses alongside cancer immunotherapies. OncoMyx was cofounded by Arizona State University professor Grant McFadden, whose lab studied the ability of a rabbit poxvirus, called myxoma virus, to kill cancer cells and attract the immune system to tumors. Boehringer Ingelheim led the financing through its venture fund, complementing its acquisition of the oncolytic virus firm ViraTherapeutics for about $245 million last year.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment